Selection from HEOR Bibliography
| Search criteria | ||||
| Austria |
||||
| The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a | ||||
| Hanne van Ballegooijen, Karin van der Hiele, Christian Enzinger, Gert de Voer, Leo H. Visser, on behalf of the CONFIDENCE Study Group | ||||
| IQVIA Netherlands, Real World Evidence, Netherlands b Department of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, Netherlands c Medical University of Graz, Graz, Austria d Merck BV, Schiphol-Rijk, The Netherlands, an affiliate of Merck KGaA, Germany e St Elisabeth Tweesteden Hospital, Tilburg, the Netherlands | ||||
| eNeurologicalSci, Volume 28, 2022, 100409, ISSN 2405-6502, https://doi.org/10.1016/j.ensci.2022.100409. (https://www.sciencedirect.com/science/article/pii/S2405650222000181) |
||||
| , Article | ||||
| , Austria, Belgium, Netherlands , Slovakia | ||||
| Abstract: https://www.sciencedirect.com/science/article/pii/S2405650222000181 | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Drug Utlization Study, Neurological disorders | 2022 | English | , Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Prospective study | |
| A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries | ||||
| Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi | ||||
| IQVIA, Courbevoie, France; Janssen EMEA, Medical Affairs, Italy; Janssen EMEA, Medical Affairs, UK | ||||
| Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA. |
||||
| , Poster | ||||
| , Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland | ||||
| Abstract: https://www.coodoc.com/pages/p1822-Daratumumab-ICPE-2019 | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology, Oncology | 2019 | English | , Public Health, Survey research | |
| Patient and caregiver indirect costs after acute cardiovascular events in Europe. | ||||
| Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5 | ||||
| 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium | ||||
| ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain |
||||
| , Oral presentation | ||||
| , Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia | ||||
| Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84816?pdfid=58963 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2018 | English | , Burden of illness, Cost of illness | |
| Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. | ||||
| Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. | ||||
| 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden. | ||||
| Clinical Epidemiology |
||||
| , Article | ||||
| , Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/ | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | , Literature Review | |
| Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries | ||||
| Duran A1, Spaepen E2,Lamotte M3, Walter E4, Umuhire D5, Lucioni C6, Pinheir B7, Brosa M8, Pujol LKB9, Van Belle S10, Annemans L11 | ||||
| 1 IMS Health, London, UK 2 SBD Analytics BVBA/SPRL, Bekkevoort, Belgium 3 IMS Health, Vilvoorde, Belgium 4 Institute for Pharmaeconomic Research, Health Economics, Vienna, Austria 5 IMS Health, Paris, France 6 Wolters Kluwer Health Italy, Milan, Italy 7 CISEP, Research Centre on the Portuguese Economy, Lisbon, Portugal 8 Oblikue Consulting, Barcelona, Spain 9 Amgen (Europe) GmbH, Zug, Switzerland 10 Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium 11 I-CHER, Ghent University, Brussels University (VUB), Ghent, Belgium | ||||
| Journal of Medical Economics Vol. 15, No. 3, 2012, 1–10 |
||||
| , Article | ||||
| , Austria, Belgium, France, Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology | 2012 | English | , Cost analysis | |
| Cost analysis of anemia treatment with erythropoieses-stimulating agents (ESAs) in patients with cancer receiving chemotherapy: a multi-country approach. | ||||
| Duran A1, Spaepen E2, Lamotte M3, Walter E4, Lucioni C5, Pinheiro B6, Brosa M7, Kutikova L8, Pujol B8, Annemans L9 | ||||
| 1 IMS Health, London, United Kingdom 2 SBD Analytics, Belgium 3 IMS Health, Vilvoorde, Belgium 4 Institute for Parmacoeconomic Research, Vienna, Austria 5 Wolters Kluwer Health Italy, Milan, Italy 6 Centre de Investigaçao Sobre Economia Portuguesa, Lisboa, Portugal 7 Oblikue Consulting, Barcelona, Spain 8 Amgen (Europe), Zug, Switzerland 9 I-CHER Interuniversity Centre for Health Economics Research, Gent, Belgium | ||||
| ISPOR 14th Annual European Congress 5-8 November 2011, Madrid, Spain |
||||
| , Poster | ||||
| , Austria, Italy, Portugal, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2011 | English | , Cost analysis | |
| Cost Analysis of Anaemia Treatment With Erythropoiesis-Stimulating Agents in Cancer Patients Receiving Chemotherapy | ||||
| Duran A1, Spaepen E2, Lamotte M3, Walter E4, Kutikova L5, Pujol B5, Ribnicsek E6, Annemans L7 | ||||
| 1IMS Health, London, UK; 2SBD Analytics BVBA/SPRL, Belgium; 3IMS Health, Vilvoorde, Belgium; 4Institut für Pharmaökonomische Forschung, Vienna, Austria; 5Amgen (Europe) GmbH, Zug, Switzerland; 6Amgen, Vienna, Austria; 7I-CHER Interuniversity Centre for Health Economics Research, UGent, VUB, Belgium | ||||
| 16th Congress of the European Association of Hospital Pharmacists, 30 March - 1 April 2011. |
||||
| , Poster | ||||
| , Austria, Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2011 | English | , Cost analysis | |
| Economic evaluation of Ranibizumab in the treatment of visual impairment due to diabetic macular edema in Austria | ||||
| Brennig C1, Schöllbauer V1, Walter E1, Gallagher M2, Knudsen MS3 | ||||
| 1Institute for Pharmaeconomic Research, Vienna, Austria, 2Novartis Pharma AG, Basel, Switzerland, 3IMS Health, London, UK | ||||
| ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
| , Poster | ||||
| , Austria | ||||
| Abstract: http://www.ispor.org/congresses/Spain1111/Posters3.aspx PDB38 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Economic evaluation | |
| Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. | ||||
| Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7, Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10, Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2 | ||||
| 1 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2 CIBER of Epidemiology and Public Health, Madrid, Spain; 3 Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 5 Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8 Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 9 Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003 Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium | ||||
| Eur Heart J. 2011 Sep;32(17):2143-52 |
||||
| , Article | ||||
| , Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21471134 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
| Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. | ||||
| Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, RodrÃguez-Artalejo F. | ||||
| BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704. |
||||
| , Article | ||||
| , Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21923932 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
| Real-Life Cost Analysis of Anemia Treatment with Erythropoiesis Stimulating Agents In Cancer Patients Receiving Chemotherapy | ||||
| Duran A1, Spaepen E2, Lamotte M3, Walter E4, Kutikova L5, Pujol B5, Annemans L6 | ||||
| 1 IMS Health, London, UK; 2 SBD Analytics BVBA/SPRL, Belgium; 3 IMS Health, Brussels, Belgium; 4 Institut fuer Pharmacoekonomische Forschung, Vienna, Austria; 5 Amgen (Europe) GmbH, Zug, Switzerland; 6 I-CHER Interuniversity Centre for Health Economics Research, Gent, Belgium | ||||
| American Society of Hematology. December 4-7, 2010 Orlando, FL. USA |
||||
| , Poster | ||||
| , Austria | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2010 | English | , Cost analysis | |
| Pharmacoeconomic evaluation of ranibizumab in the treatment of age-related macular degeneration in Austria. | ||||
| Walter E, Brennig C, Moeremans K, Thomas V | ||||
| ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece |
||||
| , Poster | ||||
| , Austria | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2008 | English | , Cost utility | |
| Health care-associated rotavirus illness in pediatric inpatients in Germany, Austria, and Switzerland. | ||||
| Foppa I, Karmaus W, Ehlken B, Fruhwirth M, Heiniger U, Plenge-Bonig A, Forster J. | ||||
| Infect Control Hosp Epidemiol. 2006; 27(6): 633-5. |
||||
| , Article | ||||
| , Austria, Germany, Switzerland | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease | 2006 | English | , Epidemiological study | |